Previous reports showed that baseline tumor IFNγ score combined with TMB improved the identification of pathological responders versus non-responders in patients with stage III melanoma treated with neoadjuvant nivolumab plus ipilimumab, when compared to either biomarker alone15. The gene discussed is IFNG; the disease is neoplasm.